Cytotherapy’s Post

Curious about how our Carcino3D™ technology works? At Carcinotech Ltd, we're dedicated to accelerating the development of cancer therapeutics. Our platform enables drug developers to access physiologically and genetically relevant models much earlier in the drug development process, bypassing the need for traditional organoid and PDX models. This streamlines R&D and pre-clinical stages, ultimately bringing treatments to market faster. Watch our video to learn more about our tumour development process. #Oncology #DrugDiscovery #CancerResearch

ICYMI, CSO Cokey Nguyen joined a Cell & Gene Live session to discuss the current and future trends of #allogeneic #Tcell therapies for oncology, and the latest manufacturing strategies and approaches to help bring these off-the-shelf treatments to patients.

🌟 Recent Advancements in CAR-T Cell Therapy The field of CAR-T cell therapy continues to evolve with groundbreaking developments: 🔬 Next-Generation Therapies: Innovative combinations, such as CAR-T cells with bispecific antibodies (TEAMs), are showing promising results in treating challenging cancers like glioblastoma. 🧬 CRISPR/Cas9 Integration: The use of CRISPR/Cas9 gene editing technology is optimizing CAR-T cells, making treatments more effective and reducing manufacturing costs. ✅ FDA Approvals: The #FDA has recently approved lisocabtagene maraleucel (liso-cel) for chronic lymphocytic leukaemia, expanding the reach of CAR-T therapies. These advancements highlight the dynamic progress in CAR-T therapy, offering new hope for cancer treatment. #CAR_Therapy #CancerResearch #Biotech #HealthcareInnovation

Asgard Therapeutics announces the selection of Exothera for process development up to clinical Phases I/II manufacturing of lead program AT-108. AT-108 is a first-in-class, off-the-shelf gene therapy that leads to personalized and potent anti-cancer immune responses. This partnership marks a significant milestone for Asgard Therapeutics as we progress towards clinical development. We are thrilled to work with Exothera - a leading provider of nucleic acid and viral vector development and manufacturing services. Click the link in the comments below to read the full press release and discover more about our groundbreaking approach to in vivo direct cell reprogramming for cancer immunotherapy. #immunotherapy #biotech #manufacturing

Global #Gene Switch Market #size was valued at USD 0.61 billion in 2022 and expected to reach USD 1.24 billion by 2029, at #CAGR of 11.03%. Request a complimentary sample copy or access the summary of the report: https://lnkd.in/d-Xc6Gym On the basis of type, #Gene Switch #Market is segmented into #CAR-T Cell Therapies, #Gene Therapies and Other #therapies.Among these two, #CAR-T cell #therapies dominated the #market in terms of #attention and #market share due to their #impressive success in treating certain forms of cancer, especially #blood cancer such as #leukaemia and #lymphoma.

$GNPX should be on your radar! Genprex, Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Advancing novel gene therapies for patients afflicted with cancer or diabetes. Our lead drug candidate, REQORSA® Immunogene Therapy (quaratusugene ozeplasmid) for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), is designed to interrupt cell signaling pathways that cause replication and proliferation of cancer cells, target and kill cancer cells, and stimulate the natural immune responses against cancer. https://lnkd.in/g9QEMbTa

🔬 AGTC Genomics Multimodal Comprehensive Gene Profiling Test is now available in select hospitals and oncology clinics across Malaysia, Vietnam, and Thailand. 🧬 Why PreciseDx CGP? 1) Revolutionary One-Test Approach: Detects over 500 actionable cancer-driving mutations, revolutionizing cancer care. 2) Precision Oncology: Tailors targeted therapy, enhancing oncologist decision-making, and eliminating trial-and-error in treatments. 3) High Accuracy: Offers precise, reliable results for better patient outcomes. 4) Cost-Effective: Accessible and affordable in the South East Asia region. 5) Local Clinical Trial Integration: Connects with local databases for the latest clinical trial information, providing additional treatment options. 🌏 This test is a game-changer, offering more options and empowering patients and oncologists to make informed decisions. 𝑬𝒎𝒑𝒐𝒘𝒆𝒓𝒊𝒏𝒈 𝑷𝒓𝒆𝒄𝒊𝒔𝒊𝒐𝒏 𝒊𝒏 𝑪𝒂𝒏𝒄𝒆𝒓 𝑪𝒂𝒓𝒆 - 𝑬𝒙𝒑𝒂𝒏𝒅𝒊𝒏𝒈 𝑶𝒑𝒕𝒊𝒐𝒏𝒔, 𝑬𝒏𝒉𝒂𝒏𝒄𝒊𝒏𝒈 𝑫𝒆𝒄𝒊𝒔𝒊𝒐𝒏𝒔. #genomics #precisionmedicine #precisiononcology #ngs

CANCER METASTASIS: Anti-lncRNA agents through the use of nanocarriers Researchers have targeted lncRNAs via iRNAs, ASOs and CRISPR-based gene editing, considering the role they play in the development and metastasis of cancer. Nanotherapeutic strategies targeting lncRNAs offer a promising and emerging approach to cancer therapeutics. #IncRNA #cancer #metastasis #nanocarriers #ChemMedChem

Check out our new paper about the preparation of transferrin-bearing, zein-based hybrid lipid nanoparticles for drug and gene delivery to prostate cancer cells, just published in Pharmaceutics. #nanomedicine #drugdelivery #genedelivery #cancerresearch https://lnkd.in/en3pThCk

CAR T-cell therapy production involves extracting, activating, genetically altering, and multiplying the patient's T-cells to target and eliminate cancer cells. Despite its revolutionary impact on cancer treatment, creating CAR-T cells is currently inconsistent, costly, and time-consuming. Patients undergoing personalized cell therapies have seen extended periods of cancer regression, but production process improvements are needed. Scientists have made substantial headway by employing high-density microfluidic bioreactors for CAR-T cell production. This groundbreaking method facilitates more effective and economical manufacturing, potentially enabling on-site production in medical facilities. #Immunotherapy #BioreactorTechnology